Pericarditis Market Report 2025

The pericarditis market size has grown strongly in recent years. It will grow from $2.32 billion in 2024 to $2.51 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increased prevalence of cardiovascular diseases, aging population and higher disease risks, improved understanding of disease pathophysiology, globalization of healthcare, drug development and innovation.

The pericarditis market size is expected to see strong growth in the next few years. It will grow to $3.45 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increased focus on precision medicine, regulatory support for orphan drugs, patient advocacy and support groups, growing research on inflammatory pathways, global efforts for cardiovascular disease prevention. Major trends in the forecast period include advances in diagnostic technologies, integration of artificial intelligence in diagnostics, management of recurrent pericarditis, telemedicine in follow-up care, patient education and support, enhancements in imaging technologies.

The anticipated rise in cardiovascular diseases is set to drive the growth of the pericarditis market. Cardiovascular diseases encompass various conditions affecting the heart or blood vessels, often associated with the accumulation of fatty deposits in arteries and an elevated risk of blood clotting. The prevalence of pericarditis, a condition that can lead to severe cardiovascular complications or even death if left untreated, is closely tied to the increasing rates of cardiovascular diseases. In the United States, an article from the Centers for Disease Control and Prevention (CDC) in October 2022 reported that a heart attack occurs every 40 seconds, with approximately 805,000 Americans experiencing a heart attack annually. The rising incidence of cardiovascular diseases, attributed to factors such as smoking, high blood pressure, and high cholesterol, is a driving force behind the pericarditis devices market's growth.

The rise in healthcare spending is expected to drive the growth of the pericarditis market in the future. Healthcare spending refers to the total financial resources allocated for various healthcare services and activities within a specific region, country, or healthcare system. An increase in healthcare expenditure fosters an environment that enhances the comprehensive management of pericarditis, encompassing research, diagnosis, treatment, and patient education, ultimately benefiting those affected by this condition. For example, a report published by the Office for National Statistics in May 2023 indicated that healthcare spending in the UK grew by 5.6% between 2022 and 2023, compared to a growth of only 0.9% in 2022. In 2023, UK healthcare expenditure reached approximately $317.63 billion (£292 billion). Thus, the increase in healthcare spending is propelling the growth of the pericarditis market.

Leading companies in the pericarditis market are focusing on innovation, introducing products such as valves for pericardial tissues to cater to broader customer bases and drive revenue growth. Valves for pericardial tissues are designed for use in cardiac surgery, particularly in procedures involving heart valve replacement or repair. Edwards Lifesciences, a US-based technology company, launched the SAPIEN 3 Ultra RESILIA valve in September 2022. This innovative valve integrates advanced anti-calcification technology, addressing a crucial factor contributing to the need for reintervention following heart valve replacement. The introduction of such products reflects a commitment to innovation, meeting the evolving needs of patients and enhancing their overall health and longevity.

Major companies in the pediatric market are focusing on the development of next-generation monoclonal antibodies to enhance treatment options, improve therapeutic outcomes, and minimize side effects for children with various medical conditions. These next-generation monoclonal antibodies are engineered to offer better efficacy, specificity, and safety in targeting diseases. For example, in January 2024, Coherus BioSciences, a US-based biotechnology company, launched LOQTORZITM. LOQTORZI is indicated for use alongside cisplatin and gemcitabine as a first-line treatment for adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC). Additionally, it can be administered as a monotherapy for patients with recurrent, unresectable, or metastatic NPC who have experienced progression after platinum-based chemotherapy, regardless of their PD-L1 status.

In March 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, acquired Arena Pharmaceuticals for USD 6.7 million. This acquisition positions Pfizer to expand its portfolio with diverse and developmental-stage therapeutic candidates in the inflammation and immunology therapeutic areas. Arena Pharmaceuticals, a US-based biopharmaceutical company, is actively developing potential therapies for immuno-inflammatory diseases, including innovative medications undergoing extensive testing for various disorders.

Major companies operating in the pericarditis market include Pfizer Inc., AstraZeneca plc, Merck & Co. Inc., Novartis International AG, Johnson & Johnson Services Inc., Takeda Pharmaceutical Co. Ltd., Zydus Cadila Healthcare Ltd., Sun Pharmaceutical Ltd., Kiniksa Pharmaceuticals Ltd., R-Pharm International LLC, Regeneron Pharmaceuticals Inc., Amgen Inc., UCB S.A., Daiichi Sankyo Company, Limited, Astellas Pharma Inc., Biogen Inc., Gilead Sciences, Inc., Merck KGaA, Ipsen S.A., and Hikma Pharmaceuticals plc.

North America was the largest region in the pericarditis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the pericarditis market report during the forecast period. The regions covered in the pericarditis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pericarditis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pericarditis is a condition characterized by inflammation and irritation of the thin, sac-such as tissue known as the pericardium, which surrounds the heart. The primary symptom is chest pain, resulting from the rubbing of inflamed sac layers against the heart.

There are three major types of pericarditis, acute pericarditis, chronic pericarditis, and recurrent pericarditis. Acute pericarditis involves a sudden and painful inflammation in the pericardium surrounding the heart. Diagnosis and treatment of pericarditis involve various methods, including electrocardiogram (ECG), echocardiogram, computerized tomography (CT), X-ray, medication, and, in some cases, surgical intervention. The treatment of pericarditis is applied in different healthcare settings, such as hospitals, clinics, medical institutes, ambulatory surgical centers, and research organizations.

The pericarditis market research report is one of a series of new reports that provides pericarditis market statistics, including pericarditis industry global market size, regional shares, competitors with a pericarditis market share, detailed pericarditis market segments, market trends and opportunities, and any further data you may need to thrive in the pericarditis industry. This pericarditis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pericarditis market consists of sales of bacterial pericarditis, viral pericarditis, constrictive pericarditis, and subacute pericarditis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The pericarditis market is segmented into bacterial pericarditis, viral pericarditis, constrictive pericarditis and other pericarditis.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.